Objectiu de la convocatòria

TRANSCAN-2 has the goal of coordinating national and regional funding programmes for research in the area of translational cancer research. The specific challenge is to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research while avoiding the duplication of efforts and ensuring a more efficient use of available resources, to produce significant results of higher quality and impact, and share data and infrastructures.
The EC co-funded call of TRANSCAN-2 (JTC 2016) will focus on: "Minimally and non-invasive methods for early detection and/or progression of cancer"
Minimally invasive methods refer to techniques that have limited physical damage, burden and pain associated with the detection method, resulting in less anticipated stress, a higher screening/clinical care uptake, and more efficient and cost-effective screening and care. The studied methods should be sensitive for early detection of cancer, its staging and prediction of progression. Examples are: individual or combination of molecular, immunochemical, proteomic or genetic markers in body fluids and blood or cell samples, as well as macroscopic, microscopic and molecular imaging techniques (e.g. improved ultrasound technology, molecular imaging with contrast agents, fluorescence imaging, radiolabelling).
This call excludes invasive methods, such as image-guided biopsy or surgery.

Característiques principals

In the context of translational cancer research, this topic will comprise three specific aims. Proposals will have to cover at least one of the specific areas listed under each undermentioned aim.

Convocatòria (URL)
http://www.transcanfp7.eu/calls/third-joint-transnational-call-jtc-2016.html

Informació addicional
Aplicatiu web:
https://secure.pt-dlr.de/ptoutline/app/transcan_2016
(Online submission will be possible from 2nd January 2017).

Requisits

Only transnational projects will be funded. Each research consortium must involve a minimum of three (3) research groups and a maximum of seven (7) research groups. The groups must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from one country (in such cases the minimum number of groups must be 4, coming from 3 different countries). The maximum number of 7 research groups could be increased only with partners from the following countries : Estonia, Latvia and Slovakia, up to a maximum of 3 additional partners from the 3 countries, to reach a maximum total of 10 research groups in a proposal.

In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, Slovakia.

Each consortium must involve at least one basic or pre-clinical research team and one clinical team.

Plase check the Call Text for detailed eligibility rules.

For Spanish applicants: please check the eligibility requirements of the institution and the principal investigator/team members, in pages 56-59 of the Call Text.

Dotació
For Spanish participants:

Durada
3 years